Obermatt
See Similar Stocks →

Immunome

NAQ:IMNM · US45257U1088
BiotechnologySmall

360

40
Medium confidence — indicative
Profit price47
Cash yield1
Price/Sales20
Price/Book28
Return on Capital30
Cash Return on Capital48
Return on Equity33
Profit margins15
Accruals67
Owner Earnings Margin4
Sales growth26
Profit growth23
Reinvestment35
Price momentum69
Debt load90
Refinancing61
Debt Payback1
Liquidity25
Analyst ratings68
Opinion Changes17
Price Target Upside65
Market mood69
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Immunome doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2006
Employees198
Websiteimmunome.com
ISINUS45257U1088
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OncologyImmunologyBiopharmaBiotechnologyMedicalPharmaceutical

Description

Immunome, Inc. (Immunome) is a biotechnology company. The company develops targeted oncology therapies. The company engages in the discovery, design, development, manufacturing, and ultimately, commercialization of antibody-drug conjugates, and othe…

Analysis

Middle-of-the-road

Immunome, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
63
2026

All-time high

66

Mar 2026

All-time low

63

Jun 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
20
—
—
—
Price/Earnings
71
—
—
—
Price/Book
28
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
37
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Immunome with its peers
Repare Therapeutics
NSQ:NULL
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →